Knop FK - Search Results

1

Plasma proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease.

Niu L, Geyer PE, Wewer Albrechtsen NJ, Gluud LL, Santos A, Doll S, Treit PV, Holst JJ, Knop FK, Vilsbøll T, Junker A, Sachs S, Stemmer K, Müller TD, Tschöp MH, Hofmann SM, Mann M. Niu L, et al. Among authors: knop fk. Mol Syst Biol. 2019 Mar 1;15(3):e8793. doi: 10.15252/msb.20188793. Mol Syst Biol. 2019. PMID: 30824564 Free PMC article.

2

No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis.

Knop FK, Vilsbøll T, Larsen S, Madsbad S, Holst JJ, Krarup T. Knop FK, et al. Diabetes Care. 2003 Sep;26(9):2581-7. doi: 10.2337/diacare.26.9.2581. Diabetes Care. 2003. PMID: 12941722 Clinical Trial.

3

The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.

Vilsbøll T, Knop FK, Krarup T, Johansen A, Madsbad S, Larsen S, Hansen T, Pedersen O, Holst JJ. Vilsbøll T, et al. Among authors: knop fk. J Clin Endocrinol Metab. 2003 Oct;88(10):4897-903. doi: 10.1210/jc.2003-030738. J Clin Endocrinol Metab. 2003. PMID: 14557471 Clinical Trial.

4

Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution.

Knop FK, Vilsbøll T, Larsen S, Højberg PV, Vølund A, Madsbad S, Holst JJ, Krarup T. Knop FK, et al. Am J Physiol Endocrinol Metab. 2007 Jan;292(1):E324-30. doi: 10.1152/ajpendo.00059.2006. Epub 2006 Sep 5. Am J Physiol Endocrinol Metab. 2007. PMID: 16954337 Free article. Clinical Trial.

5

Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus.

Knop FK, Vilsbøll T, Madsbad S, Holst JJ, Krarup T. Knop FK, et al. Diabetologia. 2007 Apr;50(4):797-805. doi: 10.1007/s00125-006-0566-z. Epub 2007 Jan 16. Diabetologia. 2007. PMID: 17225124

6

Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?

Knop FK, Vilsbøll T, Højberg PV, Larsen S, Madsbad S, Vølund A, Holst JJ, Krarup T. Knop FK, et al. Diabetes. 2007 Aug;56(8):1951-9. doi: 10.2337/db07-0100. Epub 2007 May 18. Diabetes. 2007. PMID: 17513701

7

[GLP-1-based treatment of type 2 diabetes mellitus].

Knop FK, Vilsbøll T. Knop FK, et al. Ugeskr Laeger. 2007 May 28;169(22):2095-9. Ugeskr Laeger. 2007. PMID: 17553390 Review. Danish.

8

[Effect of incretin hormones GIP and GLP-1 for the pathogenesis of type 2 diabetes mellitus].

Vilsbøll T, Knop FK. Vilsbøll T, et al. Among authors: knop fk. Ugeskr Laeger. 2007 May 28;169(22):2101-5. Ugeskr Laeger. 2007. PMID: 17553392 Review. Danish.

9

The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance.

Knop FK, Vilsbøll T, Højberg PV, Larsen S, Madsbad S, Holst JJ, Krarup T. Knop FK, et al. Regul Pept. 2007 Dec 4;144(1-3):123-30. doi: 10.1016/j.regpep.2007.07.002. Epub 2007 Jul 13. Regul Pept. 2007. PMID: 17692937

10

Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes.

Højberg PV, Zander M, Vilsbøll T, Knop FK, Krarup T, Vølund A, Holst JJ, Madsbad S. Højberg PV, et al. Among authors: knop fk. Diabetologia. 2008 Apr;51(4):632-40. doi: 10.1007/s00125-008-0943-x. Epub 2008 Feb 22. Diabetologia. 2008. PMID: 18292985

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

531 results

Search Page

Filters